Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the details for Canadian investors.

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...

Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Amazon and Google parent Alphabet are set to report earnings, along with other tech companies including AI darling Palantir, and chipmaker Advanced Micro Devices. Pharmaceutical firms Novo Nordisk, ...